Birchview Capital’s Zenas BioPharma ZBIO Stock Holding History

Birchview Capital’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38M	Buy	93,601 +23,601	+34%	+$469K	1.11%	24
2026 Q1	$1.37M	Buy	+70,000	New	+$1.57M	0.78%	33
2025 Q4	–	Sell	-16,500	Closed	-$366K	–	80
2025 Q3	$366K	Hold	16,500	–	–	0.28%	55
2025 Q2	$160K	Hold	16,500	–	–	0.16%	62
2025 Q1	$130K	Hold	16,500	–	–	0.11%	61
2024 Q4	$135K	Buy	+16,500	New	+$257K	0.11%	57

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Birchview Capital's ZBIO Position: Q2 2026 in Review

Birchview Capital increased its Zenas BioPharma (ZBIO) stake by 34% in Q2 2026, buying an estimated $469K and bringing the position to 93,601 shares worth $2.38M. The position accounts for 1.11% of the portfolio, ranked #24.

Birchview Capital first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Birchview Capital held 93,601 shares of Zenas BioPharma worth $2.38M as of Q2 2026.
Birchview Capital bought 23,601 Zenas BioPharma shares in Q2 2026, an estimated $469K.
Zenas BioPharma made up 1.11% of Birchview Capital's portfolio in Q2 2026, its #24 holding.
Birchview Capital first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.